Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Cell & Gene Therapy Asia 2019

Masafumi Onodera's Biography

Masafumi Onodera, Head, Department of Human Genetics, National Center for Child Health and Development

Field of Research:
Pediatric, Hematology, and Gene Therapy
Hokkaido University School of Medicine MD (1986)
Hokkaido University Ph. D (1994)

Professional Experience:
1986-199Dpt. Pediatrics, Hokkaido University
1990-1993 Dpt. Morphogenesis, Kumamoto University
1994-1998 Visiting fellow in NIH (Clinical Gene Therapy Branch)
1998-2001 Dpt. Immunology, Tsukuba University (Researcher)
2001-2008 Dpt. Hematology, Tsukuba University (Assistant Prof.)
2008- Dpt. Human Genetics, National Center for Child Health and Development (Head)
2009- Div. Clinical Immunology, National Center for Child Health and Development (Chief)

Masafumi Onodera Image

Gene Therapy, Past, Present, and Future

Tuesday, 12 November 2019 at 08:30

Add to Calendar ▼2019-11-12 08:30:002019-11-12 09:30:00Europe/LondonGene Therapy, Past, Present, and FutureCell and Gene Therapy Asia 2019 in Kobe, JapanKobe,

Almost 30 years ago, the first gene therapy clinical trial was conducted for severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SICD) in the US and Italy. Since then, the large number of gene therapy have been done and made steady progress despite of swings and roundabouts and currently proven to be a safe and effective therapeutic option for various intractable diseases such as primary immunodeficiencies, inherited metabolic disorders, hemoglobinopathy, inherited retinitis, hemophilia A and B, neuromuscular diseases, hematological malignancy, and some solid tumors. Furthermore, a new technology using genome editing for the diseases has been developed in rapid pace and applicable in clinical trials and then the definition of gene therapy may change from “therapy with a gene” to “therapy for a gene” in near future. Considering what coming from such a new technology sometimes carry unimaginable risks, however, the discussion from the wide angle including an ethical point of view should be needed to put into practice the new technology.  From the point of this view, we have to ask ourselves “What can we do and What should we do” to future gene therapy. I would like to think and discuss the best course of action to the progress of gene therapy together in my presentation.

Add to Calendar ▼2019-11-11 00:00:002019-11-12 00:00:00Europe/LondonCell and Gene Therapy Asia 2019Cell and Gene Therapy Asia 2019 in Kobe, JapanKobe,